For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 119,525 | 81,628* | 72,720 | 60,204 |
| General and administrative expenses | 366,358 | 472,518* | 327,177 | 341,199 |
| Total operating expenses | 485,883 | 554,146 | 399,897 | 401,403 |
| Loss from operations | -485,883 | -554,146 | -399,897 | -401,403 |
| Loss, before tax | -485,883 | -554,146 | -399,897 | -401,403 |
| Net loss | -485,883 | -554,146 | -399,897 | -401,403 |
| Basic EPS | -0.03 | -0.041 | -0.02 | -0.02 |
| Diluted EPS | -0.03 | -0.041 | -0.02 | -0.02 |
| Basic Average Shares | 16,072,267 | 13,555,969 | 16,072,267 | 16,072,267 |
| Diluted Average Shares | 16,072,267 | 13,555,969 | 16,072,267 | 16,072,267 |
Accustem Sciences Inc. (ACUT)
Accustem Sciences Inc. (ACUT)